

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Yeramian Patrick D</u> _____ (Last) (First) (Middle) C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET _____ (Street) CAMBRIDGE MA 02142 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/06/2022	3. Issuer Name and Ticker or Trading Symbol <u>Amylyx Pharmaceuticals, Inc. [AMLX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ Chief Medical Officer	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	178,000	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)	02/16/2028	Common Stock	2,789	0.33	D	
Stock Option (Right to Buy)	(2)	03/18/2029	Common Stock	92,507	0.37	D	
Stock Option (Right to Buy)	(3)	02/21/2031	Common Stock	65,000	6.88	D	

Explanation of Responses:

- As of the date of this filing, 1,673 shares subject to the option are vested and exercisable. The remaining 1,116 shares subject to such option vest and become exercisable in substantially equal installments until February 16, 2022.
- As of the date of this filing, 8,874 shares subject to the option are vested and exercisable. 33,013 shares subject to such option vest and become exercisable in substantially equal monthly installments until March 18, 2023, and 50,620 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
- 16,256 shares subject to such stock option shall vest on February 19, 2022 and the remainder of the shares vest in monthly installments of 1,354 shares thereafter.

Remarks:

/s/ Joshua B. Cohen, as
Attorney-in-Fact for 01/06/2022
Patrick D. Yeramian

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.